AlphAIAlphAI — Financial news for AI agents
tradingview.com$AMGN

Guggenheim maintains Amgen at Neutral, raises price target to $435 from $378

Guggenheim kept its Neutral rating on Amgen but raised its price target to $435 from $378, suggesting a 9.1% downside from the Nov 4 close. Recent analyst targets for Amgen range from $425 to $530.

Original reporting
tradingview.com
Published Nov 5, 2026, 4:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 4:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Guggenheim maintains Amgen at Neutral, raises price target to $435 from $378 — source image
Source · tradingview.com
Decision brief

The 30-second read

$AMGNNeutralLow
01

Why it matters

The price target increase suggests a slight bullish bias but limited trading urgency.

02

Market read

A modest analyst upgrade with limited immediate market impact.

03

What to watch

Potential upcoming clinical trial results could outweigh the modest target change.

Relevance 5/10Novelty 5/10Timing: today

Background

Guggenheim's analyst note adjusts Amgen's valuation based on recent data.

Company-level read

Ticker impact

$AMGNNeutralMedium confidence
Context

Guggenheim raised its price target on Amgen to $435 from $378, a new analyst recommendation.

Expected impact

potential downside pressure as the stock trades below the new target

Evidence & confidence

The target increase is modest and reflects a 15% uplift, but no immediate catalyst drives a strong move.

Market effects

Sector

Minimal impact on the biotech sector; other peers unlikely to move on this single target change.

Regional

US market only; no broader regional effect.

Global

Low; the update is specific to Amgen.

Counterpoint

What could challenge this read

Investors may view the target raise as insufficient given Amgen's pipeline, maintaining a sell stance.

Key entities

  • Company
    Amgen

    Biopharmaceutical company receiving a new price target.

  • Research Firm
    Guggenheim

    Analyst firm issuing the target revision.

Read at source← All news

Related articles

$AMGNMed

Freedom Broker downgrades Amgen stock rating on valuation despite raising price target

Freedom Broker downgraded Amgen (AMGN) to Hold from Buy, raising its price target to $470. The move follows strong quarterly results, with revenue and EPS beating expectations. Amgen raised its full-year guidance, and shares are up 44% year-to-date. Analysts cite strong performance but note the stock is near fair value. Other analysts, including UBS and RBC, raised their price targets.

investing.com
$AMGNLow

FDA Approval for AMJEVITA issued to AMGEN INC

The FDA approved a label update for Amgen's AMJEVITA (adalimumab-atto) on 11/05/2026, according to the company. The approval covers the 20 mg/0.4 mL and 40 mg/0.8 mL injectable products, but no new indication was disclosed. This is a routine regulatory update for an already approved product.

quantisnow.com
$AMGNMed

Amgen’s Repatha reduces heart attack risk in real-world study

Amgen's Repatha (evolocumab) reduced heart attack risk by 20% compared to ezetimibe in a real-world study of 544,103 adults with atherosclerotic cardiovascular disease, according to the company. The four-year study tracked patients from 2017 to 2024, with Repatha showing a lower cumulative incidence of heart attacks (5.88% vs. 7.76%). Amgen's chief medical officer highlighted the study's relevance for treatment decisions.

clinicaltrialsarena.com